D. Standring -
David N. Standring, Ph.D., is Executive Vice President, Biology at Idenix Pharmaceuticals and has had roles of increasing responsibility since joining Idenix as Executive Director, Research in September 2000. Prior to joining Idenix, Dr. Standring led HBV and HCV programs at Schering Plough from 1998 to 2000 and at Bristol-Myers Squibb from 1994 to 1998. From 1984 to 1994, Dr. Standring was on the faculty of the University of California at San Francisco where his laboratory elucidated
David N. Standring, Ph.D., is Executive Vice President, Biology at Idenix Pharmaceuticals and has had roles of increasing responsibility since joining Idenix as Executive Director, Research in September 2000. Prior to joining Idenix, Dr. Standring led HBV and HCV programs at Schering Plough from 1998 to 2000 and at Bristol-Myers Squibb from 1994 to 1998. From 1984 to 1994, Dr. Standring was on the faculty of the University of California at San Francisco where his laboratory elucidated mechanisms of HBV assembly among other topics. Dr. Standring holds a B.A. in Chemistry from St. John's College, Oxford University, a Ph.D. in Bioorganic Chemistry from Harvard University and did a post-doctoral fellowship in the laboratory of Prof. W. J. Rutter at UCSF. At Idenix, Dr. Standring is responsible for the preclinical biology profiling of Idenix’s novel drug candidates. These include the marketed hepatitis B drug LdT (Telbivudine), licensed to Novartis and the HIV NNRTI drug candidate, IDX899, licensed to GlaxoSmithKline. Dr. Standring’s current efforts center on three classes of novel HCV candidates: the liver-targeted nucleotide IDX184, the non-nucleoside polymerase inhibitor, IDX375, and the macrocyclic protease inhibitors, IDX136 and IDX316.